NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML
13 January 2012
Pial Ganguli
Please Login to read the full article.
13 January 2012
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- BMS' Sprycel loses out to Novartis' discounted Tasigna in England
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- Pfizer's two cancer candidates accepted for EMA review
- Gardasil and Rotarix nods mark further Japanese progress on vaccines
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
